Article · 2 Sep 2026
Review articlePublished 27 May 2016
Extended-release quetiapine fumarate in the treatment of bipolar disorder
Abstract
Select any words in the title or abstract, or press this and choose a sentence.
The management of bipolar disorder presents challenges for the clinician who is often required to prescribe a variety of medication regimes for the different phases of the illness. With a range of pharmacological actions, quetiapine fumarate is a useful option in such circumstances. Initial studies have yielded encouraging results: quetiapine fumarate is effective as monotherapy or as an adjunct to mood stabilizers in mania and in the maintenance phase, and as monotherapy in bipolar depression. The extended-release preparation with once-daily dosing may potentially enhance adherence. Studies of this formulation reveal an efficacy profile matching the immediate-release preparation. However, precise dosing schedules, metabolic consequences and the risk of other side effects will need to be considered in establishing quetiapine fumarate in the management of any individual patient.
Subjects
Neuroscience & NeurologyAsk about this article
Answers come only from this article's title, abstract and keywords, each sentence pointing to where it comes from. Your question is sent to OpenAI to write the answer. Scholars Central does not store it.
More from this journal
The newest in Neuropsychiatry.
Conferences in this field
Upcoming conferences in this field.
Follow
New articles from what you follow go into your email digest, once you agree to alert emails.
- JournalNeuropsychiatry
- SubjectNeuroscience & Neurology
- BylineArticles whose byline prints “Rajiv Weerasundera”
- BylineArticles whose byline prints “David J Castle”